We are clearly in the midst of an anomalously severe flu season.
Although H5N1 has not been detected in high numbers among humans, there's a good chance that it's quietly playing a significant role without even infecting humans directly.
How, exactly? Let's lay it all out: 🧵
If you want the answer up front without having to read through a detailed explanation, you can skip to the summary and conclusion in the last few posts of the thread.
Otherwise, read on!
To understand how influenza evolves, you need to trace the progression of the virus from its source.
All mammalian influenza A viruses are thought to originate in birds. They then find their way to certain mammals, where the viruses mutate significantly.
After finding and infecting a mammal host that scientists coldly describe as a "mixing vessel" for multiple influenza subtypes at once, viruses swap genetic material with one another. They meet each other in the same cell.
But to me, the most interesting part of this study was buried in a supplemental table.
Among the 32 reassortant viruses found, 16 unique genotypes emerged. 5 of those were H5, and 11 of them were H3.
66% of the reassortant viruses found were of H3N1 subtype instead of H5N1.
We shouldn't ascribe too much importance to this one study with a small sample size, but to me this illustrates that it's not just H5N1 itself that we need to be concerned about.
It's also the threat of existing human-transmissible subtypes acquiring genetic material from H5N1.
It stands to reason that H1/H3 influenza viruses with genes acquired from H5 viruses would face less evolutionary resistance than vice versa.
They're already optimized for transmission in humans, after all, by virtue of their hemagglutinin proteins.
I'd like to point to another example that we're all familiar with: the 1918 influenza pandemic.
What if it emerged similar to how we just described?
A human-compatible influenza H1 virus acquiring gene segments from an avian virus through reassortment?
The process of reassortment is not unusual for influenza.
The viral landscape is constantly shifting, given the many hosts providing a receptive environment for viral replication.
What's different now? A highly pathogenic H5N1 recently became more adept at infecting mammals.
To summarize the hypothesis:
Human-transmissible H1/H3 influenza A subtypes may have already acquired genetic material from H5N1 through reassortment, via mammals simultaneously infected with H1/H3 virus and H5N1.
This could explain why we're seeing increased clinical severity.
In conclusion:
If you're waiting for human-to-human transmission of H5N1 subtyped virus as the sign that the bird flu pandemic has begun, you might not need to wait any longer.
Evolution may have arrived at a simpler approach, and it's quite possible that we're already there.
Thanks to everyone sharing insight and continued coverage on this topic, including: @mrmickme2 @Nucleocapsoid @HNimanFC @RickABright @outbreakupdates @MLS_Dave @TRyanGregory
I'm probably missing a few other good accounts on this subject. Share in the replies who else to follow.
As always, please feel free to correct me if I missed anything.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
If you're new to my account, you may wonder why I spend so much of my time post Novavax availability information.
This figure summarizes my feelings on the matter.
"But I thought that all the COVID vaccines were the same?"
No, they're not. Data shows that Novavax elicits fewer adverse effects, and there are head-to-head comparisons vs mRNA showing improved protection with Novavax.
The real reason big chains are hesitant to offer COVID vaccines yet is that they're waiting on CDC recommendations from the ACIP meeting on Sep 18.
But there's no law on the books that says pharmacies need to wait for new CDC recommendations to offer vaccines in the meantime.
To be clear, it would still be a good idea to comment on ACIP, which is currently open for comment.
Leave a comment on the need to continue providing widespread access to COVID vaccines. Comment on the need to maintain shared clinical decision-making.
From that point onwards, there was a massive, concerted effort to shift media narratives to encourage mass infection, supposedly as a pro-business move.
Predictably, that was a disastrous decision in terms of public health outcomes.
Anyone who has seriously followed the research on COVID will tell you that the risk of myocarditis (among numerous other conditions) from COVID is far greater than that of Novavax.
The 3CL protease, a critical part of the viral machinery that allows SARS-CoV-2 to replicate, binds with hundreds of proteins in the liver and gut alone.